Good MorningA much-needed market correction is underway and may not end soon. The sell-off was sparked by a sell-the-news event that has yet to play out. The news was the June CPI report, which was affirmed by the PCE price index; consumer inflation is falling closer to the FOMC's target of 2%, paving the path toward an interest rate cut. The significant detail is the interest rate cut, a move that will signal the easing of economic headwinds and a pivot for the market. That pivot will be into small and mid-cap names, driven by the expectation improving business conditions will drive growth and profits.
This week's risk is the FOMC. The FOMC is meeting on Tuesday and Wednesday and will release a fresh policy statement on Wednesday. The market is pricing in a rate cut for August and a high probability for a second in September. Still, the FOMC may hesitate to commit, inducing volatility in the market. The takeaway is that underlying economic conditions and outlook remain bullish; a stock market correction should result in a buy-the-dip opportunity and fresh all-time highs later this year. Featured: When the levee breaks (Ad) 
|
Markets | | |
Some names in the retail and apparel sectors have made a splash in investors’ monitors in recent weeks, even months. Unfortunately, the attention is founded on seriously bearish price action, like the fact that shares of Lululemon Athletica Inc. (NASDAQ: LULU) are now trading at only 48% of ... Read the Full Story |
|
|
Markets | | | The earnings reports from Alphabet Inc. (NASDAQ: GOOGL) and Tesla Inc. (NASDAQ: TSLA) led technology stocks lower for the week. Some analysts are warning that the price action is due to an artificial intelligence (AI) bubble, but there could be other factors at play.
First, the second h... Read the Full Story |
|
Markets | | | The world of cryptocurrency is still a developing thesis, with some raging bulls on every coin out there and others calling the asset class a complete scam and Ponzi scheme. Whether one side is right or wrong is up for debate, but one thing remains true: investor and trader psychology and behavior.
... Read the Full Story |
|
From Our Partners | | Tesla's About to Prove Everyone Wrong... Again
Back in 2018, when Jeff Brown told everyone to buy Tesla…
The "experts" said Elon was finished and Tesla was headed for bankruptcy.
Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough. | | Click here to see why Tesla's about to prove everyone wrong... again. |
|
Stocks | | | A widespread rally swept Wall Street Friday, lifting far-reaching corners, to close a tumultuous week where stocks that had been left behind for much of this year’s record-setting run wrested the spotlight back from the market’s biggest stars.The S&P 500 jumped 1.1% for its best day in seven wee... Read the Full Story |
|
Markets | | | Owning stock gives investors a one-for-one behavior in the underlying stock, and that’s good enough when there is a longer timeframe. But it won’t cut it for big traders looking to quickly get a hit-and-run stock move.
That’s where stock options come in. They allow investors to ac... Read the Full Story |
|
From Our Partners | | Silver is trading around $33—but insiders are betting on a $70 breakout by year’s end.
With supply shrinking and demand surging from AI, EVs, and defense tech, this could be the most overlooked setup of 2025. Most investors haven’t caught on yet. | | Get the Silver Forecast before the breakout hits front-page news |
|
Markets | | | Asian shares mostly declined in cautious trading Tuesday ahead of central bank meetings around the world. The Federal Reserve, the Bank of England and the Bank of Japan are holding monetary policy meetings this week. Japan's benchmark Nikkei 225 lost 0.5% in morning trading to 38,268.72. Australia's... Read the Full Story |
|
Markets | | |
3M’s (NYSE: MMM) rebound is gaining momentum because of surprisingly good results. Today’s story is that repositioning efforts are taking hold and driving improved profitability while litigation risks dwindle. The takeaways from the Q2 report include better-than-expected top and bottom... Read the Full Story |
|
Markets | | | Two years after launching an aggressive fight against inflation and one year after leaving its benchmark interest rate at a near-quarter-century high, the Federal Reserve is expected to signal this week that it will likely reduce borrowing costs as soon as September Read the Full Story |
|
Markets | | | All of a sudden it's Kamala Harris ' economy — a major opportunity as well as a possible risk for the likely Democratic presidential nominee.Shortly after President Joe Biden left the race a week ago, Harris began to craft her own narrative around the economy by putting an emphasis on ending child p... Read the Full Story |
|
Markets | | | The Federal Reserve’s favored inflation measure remained low last month, bolstering evidence that price pressures are steadily cooling and setting the stage for the Fed to begin cutting interest rates in September Read the Full Story |
|
Monday's Early Bird Stock Of The Day Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California. | Should I Buy Edwards Lifesciences Stock? EW Bull and Bear Case Explained
These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Edwards Lifesciences was last updated on Monday, August 18, 2025 at 7:14 PM.
Edwards Lifesciences Bull Case -
The current stock price is around $78, which is near its 52-week low of $64, potentially offering a buying opportunity for investors looking for value.
-
Recent quarterly earnings showed a strong performance with earnings per share of $0.67, exceeding analyst expectations, indicating robust financial health.
-
The company reported a revenue increase of 11.9% year-over-year, suggesting strong growth potential in its market segment.
-
Edwards Lifesciences Co. has a low debt-to-equity ratio of 0.06, indicating a strong balance sheet and lower financial risk, which is attractive for conservative investors.
-
The firm has a high net margin of 72.96%, reflecting efficient operations and profitability, which can lead to higher returns for shareholders.
Edwards Lifesciences Bear Case -
Insider selling has been observed, with significant shares sold recently, which may indicate a lack of confidence among company executives.
-
The stock has experienced a decrease in ownership by insiders, which could suggest potential concerns about the company's future performance.
-
Despite strong earnings, the stock's price-to-earnings ratio of 11.26 may not reflect future growth expectations, leading to potential overvaluation risks.
-
The company has a PEG ratio of 3.78, which indicates that the stock may be overvalued relative to its growth rate, making it less attractive for growth-focused investors.
-
Market volatility, as indicated by a beta of 1.08, suggests that the stock may be more sensitive to market fluctuations, posing risks for investors during uncertain times.
| | View Today's Stock Pick |
|
